Skip to main content
. 2022 Nov 17;10(1):e200043. doi: 10.1212/NXI.0000000000200043

Table 1.

Demographic Characteristics, Type of Vaccine, SARS-CoV-2 Anti-S IgG Serostatus at t0, Anti-S IgG Titers at t1 (21–35 Days After the Second Vaccine Dose), Time Between the Second Vaccine Dose and Last Serum Sample Collected (Before Third Dose), and the Number of Breakthrough COVID-19 Cases After Vaccine for All Patients and Stratified by Disease-Modifying Treatment

graphic file with name NXI-2022-200050t1.jpg